X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2025)

X4 Pharmaceuticals has reported Operating Leases for 7 years, with the latest figure at $994000.0 in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 29.5% year-over-year to $994000.0; the trailing twelve-month figure through Dec 2025 stood at $994000.0 (down 29.5% YoY), and the FY2025 full-year result was $994000.0, down 29.5% from the prior year.
• Operating Leases for Q4 2025 stood at $994000.0, up from $95000.0 in the prior quarter.
• The five-year high for Operating Leases was $6.1 million in Q3 2021, with the low at $95000.0 in Q3 2025.
• Historically, Operating Leases has averaged $3.3 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2021 — Operating Leases surged 270.24% — and 2025, when it tumbled 94.59%.
• X4 Pharmaceuticals' Operating Leases stood at $4.8 million in 2021, then declined by 24.56% to $3.6 million in 2022, then declined by 27.5% to $2.6 million in 2023, then slumped by 46.02% to $1.4 million in 2024, then declined by 29.5% to $994000.0 in 2025.
• The last three Operating Leases figures came in at $994000.0 (Q4 2025), $95000.0 (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.